These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 12145189

  • 1. Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides.
    Müthing J, Burg M, Möckel B, Langer M, Metelmann-Strupat W, Werner A, Neumann U, Peter-Katalinic J, Eck J.
    Glycobiology; 2002 Aug; 12(8):485-97. PubMed ID: 12145189
    [Abstract] [Full Text] [Related]

  • 2. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues.
    Müthing J, Meisen I, Bulau P, Langer M, Witthohn K, Lentzen H, Neumann U, Peter-Katalinić J.
    Biochemistry; 2004 Mar 23; 43(11):2996-3007. PubMed ID: 15023051
    [Abstract] [Full Text] [Related]

  • 3. Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin.
    Müthing J, Meisen I, Kniep B, Haier J, Senninger N, Neumann U, Langer M, Witthohn K, Milosević J, Peter-Katalinić J.
    FASEB J; 2005 Jan 23; 19(1):103-5. PubMed ID: 15520251
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells.
    Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte ML, Czubayko F, Aigner A.
    Biochem Biophys Res Commun; 2004 Aug 20; 321(2):403-12. PubMed ID: 15358191
    [Abstract] [Full Text] [Related]

  • 5. Molecular characterization of the recombinant A-chain of a type II ribosome-inactivating protein (RIP) from Viscum album coloratum and structural basis on its ribosome-inactivating activity and the sugar-binding properties of the B-chain.
    Ye W, Nanga RP, Kang CB, Song JH, Song SK, Yoon HS.
    J Biochem Mol Biol; 2006 Sep 30; 39(5):560-70. PubMed ID: 17002877
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic activity of recombinant bFGF-rViscumin fusion proteins.
    Schmidt A, Möckel B, Eck J, Langer M, Gauert M, Zinke H.
    Biochem Biophys Res Commun; 2000 Oct 22; 277(2):499-506. PubMed ID: 11032750
    [Abstract] [Full Text] [Related]

  • 7. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice.
    Schaffrath B, Mengs U, Schwarz T, Hilgers RD, Beuth J, Möckel B, Lentzen H, Gerstmayer B.
    Anticancer Res; 2001 Oct 22; 21(6A):3981-7. PubMed ID: 11911280
    [Abstract] [Full Text] [Related]

  • 8. Characterization of cytosolic sialidase from Chinese hamster ovary cells: part II. Substrate specificity for gangliosides.
    Müthing J, Burg M.
    Carbohydr Res; 2001 Feb 15; 330(3):347-56. PubMed ID: 11270813
    [Abstract] [Full Text] [Related]

  • 9. Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain.
    Eck J, Langer M, Möckel B, Baur A, Rothe M, Zinke H, Lentzen H.
    Eur J Biochem; 1999 Sep 15; 264(3):775-84. PubMed ID: 10491123
    [Abstract] [Full Text] [Related]

  • 10. Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression.
    Galm O, Fabry U, Efferth T, Osieka R.
    Cancer Lett; 2002 Dec 10; 187(1-2):143-51. PubMed ID: 12359362
    [Abstract] [Full Text] [Related]

  • 11. Characterization of recombinant and plant-derived mistletoe lectin and their B-chains.
    Eck J, Langer M, Möckel B, Witthohn K, Zinke H, Lentzen H.
    Eur J Biochem; 1999 Oct 10; 265(2):788-97. PubMed ID: 10504411
    [Abstract] [Full Text] [Related]

  • 12. The sugar-combining area of the galactose-specific toxic lectin of mistletoe extends beyond the terminal sugar residue: comparison with a homologous toxic lectin, ricin.
    Lee RT, Gabius HJ, Lee YC.
    Carbohydr Res; 1994 Feb 17; 254():269-76. PubMed ID: 8180989
    [Abstract] [Full Text] [Related]

  • 13. Crystal structure at 3 A of mistletoe lectin I, a dimeric type-II ribosome-inactivating protein, complexed with galactose.
    Niwa H, Tonevitsky AG, Agapov II, Saward S, Pfüller U, Palmer RA.
    Eur J Biochem; 2003 Jul 17; 270(13):2739-49. PubMed ID: 12823544
    [Abstract] [Full Text] [Related]

  • 14. Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells.
    Müthing J, Duvar S, Heitmann D, Hanisch FG, Neumann U, Lochnit G, Geyer R, Peter-Katalinic J.
    Glycobiology; 1999 May 17; 9(5):459-68. PubMed ID: 10207178
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Discrimination of neolacto-series gangliosides with alpha2-3- and alpha2-6-linked N-acetylneuraminic acid by nanoelectrospray ionization low-energy collision-induced dissociation tandem quadrupole TOF MS.
    Meisen I, Peter-Katalinić J, Müthing J.
    Anal Chem; 2003 Nov 01; 75(21):5719-25. PubMed ID: 14588011
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency.
    Galanina OE, Kaltner H, Khraltsova LS, Bovin NV, Gabius HJ.
    J Mol Recognit; 1997 Nov 01; 10(3):139-47. PubMed ID: 9408830
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.